JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB266103

Human USP33 knockout HEK-293T cell line

Be the first to review this product! Submit a review

|

(0 Publication)

USP33 KO cell line available to order. KO validated by. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 5.

View Alternative Names

Deubiquitinating enzyme 33, EC 3 1 2 15, KIAA1097, MGC16868, OTTHUMP00000011234, OTTHUMP00000011330, OTTHUMP00000011331, UBP33_HUMAN, Ubiquitin carboxyl-terminal hydrolase 33, Ubiquitin specific peptidase 33, Ubiquitin thioesterase 33, Ubiquitin thiolesterase 33, Ubiquitin-specific-processing protease 33, VDU 1, VHL-interacting deubiquitinating enzyme 1, hVDU1, pVHL interacting deubiquitinating enzyme 1, ubiquitin specific protease 33

1 Images
Sanger Sequencing - Human USP33 knockout HEK-293T cell line (AB266103)
  • Sanger seq

Unknown

Sanger Sequencing - Human USP33 knockout HEK-293T cell line (AB266103)

Homozygous : 1 bp insertion in exon 5

Key facts

Cell type

HEK-293T

Species or organism

Human

Tissue

Kidney

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 5

Product details

Recommended control: Human wild-type HEK293T cell line (ab255449). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266103-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266103 Human USP33 knockout HEK-293T cell line", "number":"AB266103-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab266103-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab266103 Human USP33 knockout HEK-293T cell line", "number":"AB266103-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
USP33
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

USP33 also known as ubiquitin-specific peptidase 33 is an important enzyme involved in the ubiquitin-proteasome system. It has a molecular mass of about 105 kDa. USP33 acts as a deubiquitinating enzyme meaning it removes ubiquitin from target proteins which stabilizes or changes their function. You find USP33 expressed in various tissues with significant levels in the brain lung and heart. Alternate names include VDU1 and a few other names reflecting variations in biological contexts.
Biological function summary

USP33 plays roles in cellular processes like signal transduction and intracellular trafficking often as part of protein complexes. Its enzymatic activity influences the regulation of proteins tasked with moving cellular components cytoskeletal dynamics and response to hypoxia. Acting on proteins such as beta-arrestin2 USP33 influences the endocytosis and recycling of G-protein-coupled receptors (GPCRs). This role allows it to impact multiple receptor-mediated signaling pathways.

Pathways

USP33 participates in critical cellular pathways including the hypoxia response and Wnt signaling. It interacts with hypoxia-inducible factor 1-alpha (HIF-1α) modifying its stability and affecting cellular response to low oxygen levels. In the Wnt signaling pathway it modulates the activity of beta-catenin through deubiquitination which is essential for cell proliferation and differentiation. These roles highlight USP33's position within wide networks of cellular regulation influencing different proteomic interactions and outcomes.

USP33 has been linked to certain cancers and neurodegenerative diseases. Its interaction with HIF-1α connects it to tumor progression as altered USP33 expression can influence cancer cell survival in hypoxic conditions. In neurodegenerative diseases like Parkinson's changes in the deubiquitination activity of USP33 may lead to protein aggregation. Its interactions with proteins such as alpha-synuclein are relevant as these proteins play a significant role in disease pathology. Understanding USP33's functions and associations offers insight into potential therapeutic targets.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com